{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"}],"units":"Participants"}],"description":"Rescue medication is defined as any medication or transfusion, other than romiplostim and excluded medications, that is administered after enrollment to the participant with the intent of raising platelet counts or to prevent bleeding and includes concomitant medications for ITP in which the dose and/or schedule was increased. Permitted rescue medications included the following:\n\n* corticosteroids\n* platelet transfusions\n* Intravenous immunoglobulin (IVIG)\n* azathioprine\n* anti-D immunoglobulin\n* danazol","groups":[{"description":"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.","id":"OG000","title":"Romiplostim"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy analysis set","reportingStatus":"POSTED","timeFrame":"From first dose of romiplostim to the end of the treatment period, 36 months","title":"Number of Participants Reporting Use of Rescue Medications for ITP During the Treatment Period","type":"SECONDARY","unitOfMeasure":"Participants"}